Wexford Capital’s ImmuCell ICCC Stock Holding History

Wexford Capital’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-65,426	Closed	-$364K	–	137
2019 Q3	$364K	Sell	65,426 -24,574	-27%	-$144K	0.05%	95
2019 Q2	$585K	Hold	90,000	–	–	0.07%	104
2019 Q1	$572K	Buy	+90,000	New	+$642K	0.05%	77

Other funds holding ICCC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

Wexford Capital's ICCC Position: Q4 2019 in Review

Wexford Capital sold out of ImmuCell (ICCC) in Q4 2019, closing a stake of 65,426 shares — an estimated $364K sold.

Wexford Capital first reported a position in ICCC in Q1 2019 and held it in 3 quarters. The position peaked at $585K in Q2 2019. 22 funds tracked by Wall St. Rank hold ICCC as of Q4 2019.

Wexford Capital reported no remaining ImmuCell position as of Q4 2019 after selling out during the quarter.
Wexford Capital sold 65,426 ImmuCell shares in Q4 2019, an estimated $364K.
Wexford Capital first reported a position in ImmuCell in Q1 2019 and held it in 3 quarters.
Wexford Capital's ImmuCell position peaked at $585K in Q2 2019.
22 funds tracked by Wall St. Rank held ImmuCell as of Q4 2019.

Based on Wexford Capital's 13F filing for Q4 2019, filed 14 Feb 2020.